米国の抗肥満薬市場

◆英語タイトル:Anti-obesity Drugs Market in the US 2015-2019
◆発行会社/調査会社:Technavio
◆商品コード:IRTNTR6729
◆発行日:2015年7月22日
◆調査対象地域:米国
◆産業分野:製薬・医療
◆ページ数:82
◆レポート言語:英語
◆レポート形式:pdf
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[米国の抗肥満薬市場]についてメールでお問い合わせはこちら
当調査レポートでは、米国の抗肥満薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、米国の抗肥満薬市場規模及び予測、薬種類別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
*** レポート概要(サマリー)***

About Obesity
Obesity is a complex multifactorial disorder characterized by the excessive accumulation and storage of fat in the body. In the recent years, this chronic illness is being considered as a global epidemic owing to its strikingly increasing incidence rates, especially in the in low and middle-income countries. Sedentary lifestyles and lack of physical activity coupled with consumption of high-calorie diet are considered to be the most preventable causes of obesity. Being either overweight or obese is considered as a risk factor for the development of multiple chronic diseases including cardiovascular disorders such as coronary heart disease, dyslipidemia, hypertension; metabolic disorders such as diabetes; and cancers to highlight a few. Although anti-obesity drugs are available in the market, their effectiveness is restricted to maintain weight rather than cure.

Technavio’s analysts forecast the anti-obesity drugs market in the US to grow at a CAGR of 24.52% over the period 2014-2019.

[Covered in this Report]
The report covers the present scenario and the growth prospects of the anti-obesity drugs market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of the currently approved patented drugs, generics, OTC products, and the available generics that are used for the treatment of obesity.

Technavio’s report, Anti-obesity Drugs Market in the US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the
key vendors operating in this market.

[Key Vendors]
• Arena Pharmaceuticals
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Novo Nordisk
• Orexigen Therapeutics
• Vivus

[Other Prominent Vendors]
• Alizyme
• Amylin
• Boehringer Ingelheim
• Eisai
• Merck
• Norgine
• Pfizer
• Rhythm Pharmaceuticals
• Shionogi USA
• Takeda Pharmaceutical
• Zafgan

[Market Driver]
• Growing Prevalence Population
• For a full, detailed list, view our report

[Market Challenge]
• Serious Adverse Events and Multiple Drug Withdrawals
• For a full, detailed list, view our report

[Market Trend]
• Diversification of Investigational Pipeline
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** レポート目次(コンテンツ)***

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Product Profiles
04.1 Xenical
04.2 Qsymia
04.3 Belviq
04.4 Saxenda
04.5 Contrave

05.Market Research Methodology
05.1 Market Research Process
05.2 Research Methodology

06.Introduction

07.Disease Overview
07.1.1 Understanding the Disease
07.1.2 Etiology and Comorbidities
07.1.3 Classification of Obesity
07.1.4 Epidemiology
07.1.5 Economic Burden Due to Obesity

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Drug Class
09.1 Peripherally Acting Anti-obesity Drugs
09.2 Centrally Acting Anti-obesity Drugs

10.Market Segmentation by Medication Type
10.1 Monotherapies
10.2 Polytherapies

11.Buying Criteria

12.Market Growth Drivers

13.Drivers and Their Impact

14.Market Challenges

15.Impact of Drivers and Challenges

16.Market Trends

17.Trends and Their Impact

18.Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2014
18.2.1 F. Hoffmann-La Roche
18.2.2 GlaxoSmithKline
18.2.3 Vivus
18.2.4 Arena Pharmaceuticals
18.2.5 Orexigen Therapeutics
18.2.6 Novo Nordisk
18.3 Other Prominent Vendors

19.Key Vendor Analysis
19.1 Arena Pharmaceuticals
19.1.1 Key Facts
19.1.2 Business Overview
19.1.3 Geographical Segmentation
19.1.4 Business Strategy
19.1.5 Recent Developments
19.1.6 SWOT Analysis
19.2 F. Hoffmann-La Roche
19.2.1 Key Facts
19.2.2 Business Overview
19.2.3 Business Segmentation
19.2.4 Business Segmentation by Revenue 2012 and 2013
19.2.5 Geographical Segmentation by Revenue
19.2.6 Business Strategy
19.2.7 Key Information
19.2.8 SWOT Analysis
19.3 GlaxoSmithKline
19.3.1 Key Facts
19.3.2 Business Overview
19.3.3 Business Segmentation
19.3.4 Business Segmentation by Revenue 2012 and 2013
19.3.5 Sales by Geography
19.3.6 Pipeline Products
19.3.7 Business Strategy
19.3.8 Key Information
19.3.9 SWOT Analysis
19.4 Orexigen Therapeutics
19.4.1 Key Facts
19.4.2 Business Overview
19.4.3 Business Strategy
19.4.4 Recent Developments
19.4.5 SWOT Analysis
19.5 Vivus
19.5.1 Key Facts
19.5.2 Business Overview
19.5.3 Business Segmentation by Revenue 2013
19.5.4 Business Segmentation by Revenue 2012 and 2013
19.5.5 Geographical Segmentation by Revenue 2013
19.5.6 Business Strategy
19.5.7 Recent Information
19.5.8 SWOT Analysis
19.6 Novo Nordisk
19.6.1 Key Facts
19.6.2 Business Overview
19.6.3 Business Segmentation by Revenue 2013
19.6.4 Business Segmentation by Revenue 2012 and 2013
19.6.5 Sales by Geography
19.6.6 Business Strategy
19.6.7 Key Information
19.6.8 SWOT Analysis

20.Other Reports in This Series

[List of Exhibits]

Exhibit 1: Market Research Methodology
Exhibit 2: Causes and Comorbidities of Obesity
Exhibit 3: Prevalence of Adults Overweight or Obese in US
Exhibit 4: Prevalence of Adults Overweight or Obese in US
Exhibit 5: Prevalence Rate of Children Overweight or Obese in US
Exhibit 6: Anti-obesity Drugs Market in US 2014-2019 ($ millions)
Exhibit 7: Segmentation of Anti-obesity Drugs Market in US by Drug Class
Exhibit 8: Segmentation of Anti-obesity Drugs Market in US by Medication Type
Exhibit 9: Pipeline Snapshot
Exhibit 10: Key Takeaways: F. Hoffman-La Roche
Exhibit 11: Key Takeaways: GlaxoSmithKline
Exhibit 12: Key Takeaways: Vivus
Exhibit 13: Key Takeaways: Arena Pharmaceuticals
Exhibit 14: Key Takeaways: Orexigen
Exhibit 15: Key Takeaways: Novo Nordisk
Exhibit 16: Arena Pharmaceuticals: Geographical Segmentation
Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
Exhibit 19: F. Hoffmann-La Roche: Revenue of Pharmaceuticals Division by Geography 2013
Exhibit 20: F. Hoffmann-La Roche: Revenue of Diagnostics Division by Geography 2013
Exhibit 21: GlaxoSmithKline: Business Segmentation 2013
Exhibit 22: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 23: GlaxoSmithKline: Sales by Geography 2013
Exhibit 24: GlaxoSmithKline: Pipeline Products 2013
Exhibit 25: Vivus: Business Segmentation by Revenue 2013
Exhibit 26: Vivus: Business Segmentation by Revenue 2012 and 2013 ($ millions)
Exhibit 27: Vivus: Geographical Segmentation by Revenue 2013
Exhibit 28: Novo Nordisk: Business Segmentation by Revenue 2013
Exhibit 29: Novo Nordisk: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 30: Novo Nordisk: Sales by Geography 2013



*** 掲載企業 ***

Arena Pharmaceuticals, F. Hoffmann-La Roche, GlaxoSmithKline, Novo Nordisk, Orexigen Therapeutics, Vivus, Alizyme, Amylin, Boehringer Ingelheim, Eisai, Merck, Norgine, Pfizer, Rhythm Pharmaceuticals, Shionogi USA, Takeda Pharmaceutical, Zafgan

*** レポートのキーワード ***

抗肥満薬、肥満治療薬、医薬品、米国

*** 調査方法 ***

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR6729 )"米国の抗肥満薬市場" (英文:Anti-obesity Drugs Market in the US 2015-2019)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。